systemic%20lupus%20erythematosus%20(pediatric)
SYSTEMIC LUPUS ERYTHEMATOSUS (PEDIATRIC)
Systemic lupus erythematosus is a chronic, multisystem, inflammatory, autoimmune disorder characterized by formation of autoantibodies directed against self-antigens and immune-complex formation.
It can be suspected when ≥2 organ systems are involved.
It is predominantly diagnosed in females of childbearing age, rarely diagnosed before 8 years old.
Clinical presentation varies in different patients and the disease activity varies over time in a single patient. Majority of patients have arthralgia of the hand.

Monitoring

  • Monitoring during clinic visit should include:
    • History-taking
    • Physical exam
    • Lab tests
      • Complete blood count (CBC)
      • Creatinine measurement
      • Urinalysis
  • Results of lab tests that may precede a disease flare:
    • Decrease in serum complement levels
    • Increase in anti-double stranded deoxyribonucleic acid (dsDNA)
    • Increase in erythrocyte sedimentation rate (ESR)
    • Decrease in hemoglobin level, leukocyte or platelet counts
    • Increase in creatine phosphokinase (CPK) levels
    • Appearance of microscopic hematuria or proteinuria

Comorbidities & Complications of Systemic Lupus Erythematosus (SLE)

  • Comorbidities for which systemic lupus erythematosus (SLE) patients are at an increased risk include infections, hypertension, atherosclerosis, dyslipidemia, diabetes, osteoporosis, avascular necrosis & malignancies

Neuropsychiatric Systemic Lupus Erythematosus (NPSLE)

  • Monitor systemic lupus erythematosus (SLE) patients for neurological &/or psychiatric manifestations as in non-neuropsychiatric systemic lupus erythematosus (NPSLE) patients
  • Usually appears w/in 1 year from the time of diagnosis; may also appear before or at the time of diagnosis
  • Diagnostic work-up may include the following:
    • Lumbar puncture
    • Nerve conduction studies (NCS)
    • Neuropsychological assessment of cognitive function
    • Neuroimaging: T1/T2 magnetic resonance imaging (MRI), diffusion-weighted imaging, gadolinium-enhanced T1 sequences
    • Cerebrospinal fluid (CSF) analysis
    • Electroencephalography (EEG)
  • Patients found to have neuropsychiatric systemic lupus erythematosus (NPSLE) should be referred to a team of psychiatrists, psychologists, neurologist & rheumatologist

Toxicity

  • Patients on long-term glucocorticoids should be monitored for:
    • Electrolyte, glucose & lipid levels to identify metabolic conditions
    • Bone densitometry to identify osteoporosis & monitor response to treatment
  • Patients on Hydroxychloroquine should have ophthalmological exam every 6-12 months to detect retinal toxicity
  • Patients on immunosuppressants should be monitored for hematologic, liver & renal toxicity, & occurrence of infection

Lupus Nephritis

  • Patients suspected to have lupus nephritis should immediately undergo renal biopsy to confirm diagnosis, evaluate severity, determine prognosis & therapy
  • Indications for renal biopsy in systemic lupus erythematosus (SLE) patients
    • Unexplained increase in serum creatinine in the absence of alternative causes (eg sepsis, hypovolemia, medications)
    • Confirmed proteinuria (≥1.0 gm/24 hours)
    • Presence of the following (result of 2 tests done w/in a short period of time, w/o other causes):
      • Proteinuria of >5.0 gm/24 hours & hematuria [≥5 red blood cells/high-power field (RBCs/hpf)] or
      • Proteinuria of >5.0 gm/24 hours & cellular casts
  • Recommended tests used for monitoring of lupus nephritis:
  •  

      Active nephritis at onset of treatment Previous active nephritis, none currently No prior or current nephritis
    Blood pressure 1 3 3
    Urinalysis 1 3 6
    Protein/ Creatinine ratio 1 3 6
    PSerum creatinine 1 3 6
    C3/C4 levels 2 3 6
    Anti-DNA 1 3 3

    *Values are at monthly intervals indicating minimum time at which the test should be measured
    Modified from: 2012 American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 13 Oct 2016
Children born to obese mothers are at increased risk of developing autism spectrum disorder (ASD) compared with children born to normal-weight mothers, according to data from a review and meta-analysis.
Yap Te-Lu, Anette Sundfor Jacobsen, 01 Oct 2013

Antenatal hydronephrosis (ANH) is a general term used to describe the dilatation of the fetal renal pelvis and/or its calyces. In pelviectasis, there is only dilatation of the renal pelvis; while in caliectasis, there is dilatation of the calyces. ANH is the most commonly diagnosed congenital urinary tract anomaly, which is detected by prenatal screening in 1–5% of all pregnancies

Yap Te-Lu, Anette Sundfor Jacobsen, 01 Dec 2012

Antenatal hydronephrosis (ANH) is a general term used to describe the dilatation of the fetal renal pelvis and/or its calyces. In pelviectasis, there is only dilatation of the renal pelvis; while in caliectasis, there is dilatation of the calyces. ANH is the most commonly diagnosed congenital urinary tract anomaly, which is detected by prenatal screening in 1–5% of all pregnancies.

Yap Te-Lu, Anette Sundfor Jacobsen, 01 Apr 2011

Antenatal hydronephrosis (ANH) is a general term used to describe the dilatation of the fetal renal pelvis and/or its calyces. In pelviectasis, there is only dilatation of the renal pelvis; while in caliectasis, there is dilatation of the calyces. ANH is the most commonly diagnosed congenital urinary tract anomaly, which is detected by prenatal screening in 1–5% of all pregnancies.